{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:44:53Z","timestamp":1791247493187,"version":"4.1.0"},"reference-count":158,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"<jats:p>Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement in 1998. Guidance initially was based on the result from a single randomized, placebo-controlled clinical trial conducted in 1996\u20131997 describing an overall reduction in RSV hospitalization rate from 10.6% among placebo recipients to 4.8% among children who received prophylaxis. The results of a second randomized, placebo-controlled trial of children with hemodynamically significant heart disease were published in 2003 and revealed a reduction in RSV hospitalization rate from 9.7% in control subjects to 5.3% among prophylaxis recipients. Because no additional controlled trials regarding efficacy were published, AAP guidance has been updated periodically to reflect the most recent literature regarding children at greatest risk of severe disease. Since the last update in 2012, new data have become available regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effects of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, and the effect of prophylaxis on wheezing and palivizumab-resistant RSV isolates. These data enable further refinement of AAP guidance to most clearly focus on those children at greatest risk.<\/jats:p>","DOI":"10.1542\/peds.2014-1666","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T04:00:34Z","timestamp":1406606434000},"page":"e620-e638","source":"Crossref","is-referenced-by-count":325,"title":["Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection"],"prefix":"10.1542","volume":"134","author":[{"name":"COMMITTEE ON INFECTIOUS DISEASES and BRONCHIOLITIS GUIDELINES COMMITTEE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Byington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dele","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon E.","family":"Schutze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney E.","family":"Willoughby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis E.","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn L.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan S.","family":"Lieberthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Cody","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Alverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill E.","family":"Baley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Gadomski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar F.","family":"Maraqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneida A.","family":"Mendonca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran J.","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Zorc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danette","family":"Stanko-Lopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinsi","family":"Hern\u00e1ndez-Cancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"key":"2021120903442536400_B1","unstructured":"Synagis Package Insert. Gaithersburg, MD: MedImmune; April 2013. Available at: www.medimmune.com\/docs\/default-source\/pdfs\/prescribing-information-for-synagis.pdf. Accessed April 24, 2014"},{"issue":"16","key":"2021120903442536400_B2","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1128\/JVI.02699-09","article-title":"Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.","volume":"84","author":"Huang","year":"2010","journal-title":"J Virol"},{"issue":"3","key":"2021120903442536400_B3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.","volume":"102","author":"IMpact-RSV study group","year":"1998","journal-title":"Pediatrics"},{"issue":"4","key":"2021120903442536400_B4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"2021120903442536400_B5","first-page":"609","article-title":"Respiratory syncytial virus.","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"key":"2021120903442536400_B6","article-title":"Policy statement: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","author":"American Academy of Pediatrics","year":"2014","journal-title":"Pediatrics"},{"issue":"5","key":"2021120903442536400_B7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","article-title":"Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV.","volume":"102","author":"American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn","year":"1998","journal-title":"Pediatrics"},{"issue":"6 pt 1","key":"2021120903442536400_B8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1542\/peds.112.6.1442","article-title":"Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.","volume":"112","author":"American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn","year":"2003","journal-title":"Pediatrics"},{"key":"2021120903442536400_B9","first-page":"560","article-title":"Respiratory syncytial virus","volume-title":"Red Book: 2006 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2006"},{"issue":"6","key":"2021120903442536400_B10","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"From the American Academy of Pediatrics: Policy statements\u2013Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.","volume":"124","author":"Committee on Infectious Diseases","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"2021120903442536400_B11","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2021120903442536400_B12","first-page":"141","article-title":"Respiratory syncytial virus activity\u2014United States, July 2011-January 2013.","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"35","key":"2021120903442536400_B13","first-page":"1203","article-title":"Respiratory syncytial virus\u2014United States, July 2007-June 2011.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120903442536400_B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1542\/peds.2012-3877","article-title":"Trends in bronchiolitis hospitalizations in the United States, 2000-2009.","volume":"132","author":"Hasegawa","year":"2013","journal-title":"Pediatrics"},{"key":"2021120903442536400_B15"},{"issue":"19","key":"2021120903442536400_B16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2021120903442536400_B17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1542\/peds.2013-0982","article-title":"Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.","volume":"132","author":"Yoshihara","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903442536400_B18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/INF.0b013e3181b34e52","article-title":"High incidence of recurrent wheeze in children with Down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection.","volume":"29","author":"Bloemers","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2021120903442536400_B19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/INF.0b013e3181d7ffa5","article-title":"Down syndrome and respiratory syncytial virus infection.","volume":"29","author":"Megged","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120903442536400_B20","first-page":"CD007743","article-title":"Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.","volume":"2","author":"Robinson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2021120903442536400_B21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab.","volume":"203","author":"Zhu","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"2021120903442536400_B22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jir790","article-title":"Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.","volume":"205","author":"Zhu","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"2021120903442536400_B23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2007.11.012","article-title":"Human respiratory syncytial virus and other viral infections in infants receiving palivizumab.","volume":"42","author":"Boivin","year":"2008","journal-title":"J Clin Virol"},{"issue":"4","key":"2021120903442536400_B24","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2021120903442536400_B25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/archpediatrics.2010.298","article-title":"Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.","volume":"165","author":"Hampp","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"11","key":"2021120903442536400_B26","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/INF.0b013e318266bf89","article-title":"Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.","volume":"31","author":"Carroll","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120903442536400_B27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jpeds.2009.12.016","article-title":"Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.","volume":"156","author":"Hampp","year":"2010","journal-title":"J Pediatr"},{"key":"2021120903442536400_B28","unstructured":"Public Health England. Respiratory syncytial virus. In: Green Book. London, England: Public Health England; 2013:1\u201313. Available at: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/148494\/Green-Book-Chapter-27a-dh_130131.pdf. Accessed April 24, 2014"},{"issue":"3","key":"2021120903442536400_B29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.prrv.2009.06.002","article-title":"Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.","volume":"10","author":"Fitzgerald","year":"2009","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"2021120903442536400_B30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/INF.0b013e3182184ae7","article-title":"Epidemiology and prevention of respiratory syncytial virus infections among infants and young children.","volume":"30","author":"Langley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903442536400_B31","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1067\/S0022-3476(03)00510-9","article-title":"Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.","volume":"143","author":"Leader","year":"2003","journal-title":"J Pediatr"},{"issue":"15","key":"2021120903442536400_B32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children, 1980-1996.","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"2021120903442536400_B33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.","volume":"31","author":"Stockman","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120903442536400_B34","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"2021120903442536400_B35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"2021120903442536400_B36","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cis211","article-title":"Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993\u20132008.","volume":"54","author":"Zhou","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2021120903442536400_B37","first-page":"1","article-title":"Births: preliminary data for 2012.","volume":"62","author":"Hamilton","year":"2013","journal-title":"Natl Vital Stat Rep"},{"issue":"6","key":"2021120903442536400_B38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"issue":"1","key":"2021120903442536400_B39","first-page":"55","article-title":"Respiratory syncytial virus and premature infants born at 32 weeks\u2019 gestation or earlier: hospitalization and economic implications of prophylaxis.","volume":"154","author":"Stevens","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"12","key":"2021120903442536400_B40","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapediatrics.2013.2636","article-title":"Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.","volume":"167","author":"Winterstein","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2021120903442536400_B41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00246-009-9577-0","article-title":"Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.","volume":"31","author":"Chang","year":"2010","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"2021120903442536400_B42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1542\/peds.2004-0224","article-title":"Economic analysis of palivizumab in infants with congenital heart disease.","volume":"114","author":"Yount","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"2021120903442536400_B43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/08035250500447944","article-title":"Respiratory syncytial virus infections in congenital heart defects\u2014hospitalizations and costs.","volume":"95","author":"Meberg","year":"2006","journal-title":"Acta Paediatr"},{"issue":"10","key":"2021120903442536400_B44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/adc.2003.046714","article-title":"Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.","volume":"89","author":"Duppenthaler","year":"2004","journal-title":"Arch Dis Child"},{"issue":"11","key":"2021120903442536400_B45","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1517\/14712598.7.11.1615","article-title":"Palivizumab in congenital heart disease: should international guidelines be revised?","volume":"7","author":"Geskey","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"2021120903442536400_B46","doi-asserted-by":"crossref","first-page":"523.e11","DOI":"10.1016\/j.cjca.2010.12.064","article-title":"Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.","volume":"27","author":"Harris","year":"2011","journal-title":"Can J Cardiol"},{"issue":"3","key":"2021120903442536400_B47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.prrv.2009.06.003","article-title":"Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes.","volume":"10","author":"Resch","year":"2009","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"2021120903442536400_B48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/INF.0b013e31805d01e3","article-title":"Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course.","volume":"26","author":"Wilkesmann","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120903442536400_B49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cis844","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus.","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2021120903442536400_B50","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dkt111","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.","volume":"68","author":"Shah","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2021120903442536400_B51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/infdis\/jit832","article-title":"Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease.","volume":"209","author":"Kim","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"2021120903442536400_B52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1542\/peds.2007-1102","article-title":"Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age.","volume":"121","author":"El Saleeby","year":"2008","journal-title":"Pediatrics"},{"issue":"10","key":"2021120903442536400_B53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/INF.0b013e31829dff4d","article-title":"Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children.","volume":"32","author":"Asner","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903442536400_B54","article-title":"Respiratory syncytial virus infections in children with cancer.","author":"Chemaly","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2021120903442536400_B55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/petr.12022","article-title":"The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy.","volume":"17","author":"Lo","year":"2013","journal-title":"Pediatr Transplant"},{"issue":"8","key":"2021120903442536400_B56","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbmt.2013.05.005","article-title":"Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients.","volume":"19","author":"Renaud","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2021120903442536400_B57","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2012.12.019","article-title":"Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.","volume":"19","author":"Seo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2021120903442536400_B58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1399-3046.2008.01017.x","article-title":"Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers.","volume":"13","author":"Michaels","year":"2009","journal-title":"Pediatr Transplant"},{"issue":"6","key":"2021120903442536400_B59","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1399-3046.2012.01744.x","article-title":"RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative.","volume":"16","author":"Danziger-Isakov","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"4","key":"2021120903442536400_B60","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-0788","article-title":"Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis\u2014a prospective birth-cohort study.","volume":"120","author":"Bloemers","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"2021120903442536400_B61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jpeds.2011.11.004","article-title":"Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study.","volume":"160","author":"Zachariah","year":"2012","journal-title":"J Pediatr"},{"issue":"2","key":"2021120903442536400_B62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ppul.20751","article-title":"Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.","volume":"43","author":"Giebels","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"2021120903442536400_B63","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.22711","article-title":"Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.","volume":"48","author":"Winterstein","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2021120903442536400_B64","first-page":"A178","article-title":"A phase IV study of the safety of palivizumab for prophylaxis of RSV disease in children with cystic fibrosis","volume":"2","author":"Cohen","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"6","key":"2021120903442536400_B65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/cid\/cir928","article-title":"Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.","volume":"54","author":"Kristensen","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2021120903442536400_B66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1440-1754.2012.02593.x","article-title":"Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?","volume":"48","author":"Elnazir","year":"2012","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"2021120903442536400_B67","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ppul.20922","article-title":"North American synagis prophylaxis survey.","volume":"44","author":"Giusti","year":"2009","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"2021120903442536400_B68","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/JCM.02132-10","article-title":"High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan.","volume":"49","author":"Yamaguchi","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"25","key":"2021120903442536400_B69","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncytial virus and parainfluenza virus.","volume":"344","author":"Hall","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"2021120903442536400_B70","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJM197903083001004","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.","volume":"300","author":"Henderson","year":"1979","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120903442536400_B71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00002018-200326040-00005","article-title":"Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.","volume":"26","author":"Lacaze-Masmonteil","year":"2003","journal-title":"Drug Saf"},{"issue":"11","key":"2021120903442536400_B72","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/01.inf.0000183938.33484.bd","article-title":"Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.","volume":"24","author":"Null","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120903442536400_B73","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/314523","article-title":"Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.","volume":"178","author":"Malley","year":"1998","journal-title":"J Infect Dis"},{"issue":"7","key":"2021120903442536400_B74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/INF.0000000000000240","article-title":"Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.","volume":"33","author":"Ramilo","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2021120903442536400_B75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/INF.0b013e3181d76d61","article-title":"Nosocomial transmission of respiratory syncytial virus in neonatal intensive care and intermediate care units: a prospective epidemiologic study.","volume":"29","author":"Berger","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120903442536400_B76","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/INF.0b013e3181a0ad01","article-title":"Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit.","volume":"28","author":"Katz","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"15","key":"2021120903442536400_B77","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2146\/ajhp120526","article-title":"Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.","volume":"70","author":"Ohler","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2021120903442536400_B78","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1067\/S0022-3476(03)00511-0","article-title":"Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease.","volume":"143","author":"Simoes","year":"2003","journal-title":"J Pediatr"},{"issue":"6","key":"2021120903442536400_B79","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1542\/peds.2009-2346","article-title":"The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.","volume":"124","author":"Meissner","year":"2009","journal-title":"Pediatrics"},{"key":"2021120903442536400_B80"},{"issue":"7","key":"2021120903442536400_B81","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00006454-200007000-00002","article-title":"Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study.","volume":"19","author":"Carbonell-Estrany","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120903442536400_B82","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-200109000-00010","article-title":"Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons.","volume":"20","author":"Carbonell-Estrany","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120903442536400_B83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1542\/peds.2004-2795","article-title":"Effect of altitude on hospitalizations for respiratory syncytial virus infection.","volume":"117","author":"Choudhuri","year":"2006","journal-title":"Pediatrics"},{"issue":"9","key":"2021120903442536400_B84","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/01.inf.0000136869.21397.6b","article-title":"Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.","volume":"23","author":"Figueras-Aloy","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120903442536400_B85","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.inf.0000137568.71589.bd","article-title":"The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.","volume":"23","author":"Law","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903442536400_B86","first-page":"2407","article-title":"Respiratory syncytial virus","volume-title":"Feigin & Cherry\u2019s Textbook of Pediatric Infectious Diseases","author":"Meissner","year":"2013","edition":"7th ed."},{"issue":"10","key":"2021120903442536400_B87","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1097\/INF.0b013e31825cef14","article-title":"Meteorologic conditions and respiratory syncytial virus activity.","volume":"31","author":"Herv\u00e1s","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"2021120903442536400_B88","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1651-2227.2003.tb00502.x","article-title":"Respiratory syncytial virus infection\u2014risk factors for hospital admission: a case-control study.","volume":"92","author":"Nielsen","year":"2003","journal-title":"Acta Paediatr"},{"issue":"3","key":"2021120903442536400_B89","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/INF.0000000000000096","article-title":"Malnutrition: a risk factor for severe respiratory syncytial virus infection and hospitalization.","volume":"33","author":"Paynter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2021120903442536400_B90","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta15050","article-title":"Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.","volume":"15","author":"Wang","year":"2011","journal-title":"Health Technol Assess"},{"issue":"3","key":"2021120903442536400_B91","doi-asserted-by":"crossref","DOI":"10.1542\/peds.99.3.e9","article-title":"PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.","volume":"99","author":"Wang","year":"1997","journal-title":"Pediatrics"},{"issue":"2","key":"2021120903442536400_B92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3476(95)70547-3","article-title":"Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.","volume":"126","author":"Wang","year":"1995","journal-title":"J Pediatr"},{"issue":"5","key":"2021120903442536400_B93","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/INF.0b013e318201813b","article-title":"Hospitalizations due to respiratory syncytial virus in children with congenital malformations.","volume":"30","author":"Zachariah","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120903442536400_B94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.inf.0000069796.72540.0a","article-title":"Maternal respiratory syncytial virus antibody titers: season and children matter.","volume":"22","author":"Le Saux","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903442536400_B95","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/INF.0b013e318157da82","article-title":"Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance.","volume":"26","author":"Panozzo","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"13","key":"2021120903442536400_B96","first-page":"1847","article-title":"Lower respiratory tract infections in Inuit infants on Baffin Island.","volume":"164","author":"Banerji","year":"2001","journal-title":"CMAJ"},{"issue":"7","key":"2021120903442536400_B97","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/jmv.21790","article-title":"Viral respiratory infections in hospitalized and community control children in Alaska.","volume":"82","author":"Singleton","year":"2010","journal-title":"J Med Virol"},{"issue":"4","key":"2021120903442536400_B98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3111\/13696990903442155","article-title":"The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.","volume":"12","author":"Tam","year":"2009","journal-title":"J Med Econ"},{"issue":"7","key":"2021120903442536400_B99","first-page":"563","article-title":"Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004.","volume":"12","author":"Young","year":"2007","journal-title":"Paediatr Child Health (Oxford)"},{"key":"2021120903442536400_B100","unstructured":"Alaska State Virology Laboratory Weekly Report, April 12\u201319, 2004. Available at: http:\/\/dhss.alaska.gov\/dph\/labs\/documents\/pdfs\/ASVL_WeeklyReport.pdf. Accessed April 24, 2014"},{"issue":"2 pt 1","key":"2021120903442536400_B101","article-title":"Respiratory syncytial virus infection in Navajo and White Mountain Apache children.","volume":"110","author":"Bockova","year":"2002","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903442536400_B102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00006454-200001000-00004","article-title":"Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children.","volume":"19","author":"Lowther","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120903442536400_B103","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2021120903442536400_B104","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"issue":"7","key":"2021120903442536400_B105","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kws299","article-title":"Disparities between black and white children in hospitalizations associated with acute respiratory illness and laboratory-confirmed influenza and respiratory syncytial virus in 3 US counties\u20142002-2009.","volume":"177","author":"Iwane","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2021120903442536400_B106","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1185\/03007995.2010.505126","article-title":"Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children.","volume":"26","author":"Welliver","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2021120903442536400_B107","unstructured":"US Food and Drug Administration. Memorandum. Background package for BLA 125283 motavizumab. 2010. Available at: www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/antiviraldrugsadvisorycommittee\/ucm213825.pdf. Accessed April 24, 2014"},{"issue":"3","key":"2021120903442536400_B108","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.","volume":"368","author":"Wu","year":"2007","journal-title":"J Mol Biol"},{"issue":"1","key":"2021120903442536400_B109","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"issue":"4","key":"2021120903442536400_B110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/INF.0b013e31818ffd03","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.","volume":"28","author":"Abarca","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903442536400_B111","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2431-10-38","article-title":"A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.","volume":"10","author":"Fern\u00e1ndez","year":"2010","journal-title":"BMC Pediatr"},{"issue":"2","key":"2021120903442536400_B112","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"},{"issue":"6","key":"2021120903442536400_B113","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3074","article-title":"Relative impact of influenza and respiratory syncytial virus in young children.","volume":"124","author":"Bourgeois","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021120903442536400_B114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1086\/653534","article-title":"Palivizumab-resistant human respiratory syncytial virus infection in infancy.","volume":"51","author":"Adams","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"15","key":"2021120903442536400_B115","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJMoa1211592","article-title":"Rhinovirus wheezing illness and genetic risk of childhood-onset asthma.","volume":"368","author":"Cal\u0131\u015fkan","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2021120903442536400_B116","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1164\/rccm.200802-309OC","article-title":"Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children.","volume":"178","author":"Jackson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2021120903442536400_B117","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1378\/chest.10-0365","article-title":"Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins.","volume":"138","author":"Poorisrisak","year":"2010","journal-title":"Chest"},{"issue":"2","key":"2021120903442536400_B118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.200406-730OC","article-title":"Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.","volume":"171","author":"Sigurs","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9178","key":"2021120903442536400_B119","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"2021120903442536400_B120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2007.02.032","article-title":"Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.","volume":"151","author":"Simoes","year":"2007","journal-title":"J Pediatr"},{"issue":"17","key":"2021120903442536400_B121","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/jama.2012.476","article-title":"Choosing wisely: helping physicians and patients make smart decisions about their care.","volume":"307","author":"Cassel","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"2021120903442536400_B122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7326\/0003-4819-136-3-200202050-00012","article-title":"Medical professionalism in the new millennium: a physician charter.","volume":"136","author":"ABIM Foundation. American Board of Internal Medicine","year":"2002","journal-title":"Ann Intern Med"},{"issue":"14","key":"2021120903442536400_B123","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMp1401335","article-title":"Promoting population health through financial stewardship.","volume":"370","author":"Ubel","year":"2014","journal-title":"N Engl J Med"},{"key":"2021120903442536400_B124","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1136\/thoraxjnl-2011-201054c.170","article-title":"A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK.","volume":"66","author":"Bentley","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"2021120903442536400_B125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2191-1991-3-18","article-title":"A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom.","volume":"3","author":"Bentley","year":"2013","journal-title":"Health Econ Rev"},{"issue":"1","key":"2021120903442536400_B126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1824-7288-35-4","article-title":"Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants.","volume":"35","author":"Chirico","year":"2009","journal-title":"Ital J Pediatr"},{"issue":"6","key":"2021120903442536400_B127","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1542\/peds.2009-2681","article-title":"The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.","volume":"124","author":"Krilov","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"2021120903442536400_B128","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1185\/03007990802484234","article-title":"The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.","volume":"24","author":"Lanct\u00f4t","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2021120903442536400_B129","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3111\/13696998.2012.690013","article-title":"Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.","volume":"15","author":"Mahadevia","year":"2012","journal-title":"J Med Econ"},{"issue":"10","key":"2021120903442536400_B130","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1651-2227.2011.02309.x","article-title":"Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.","volume":"100","author":"Neovius","year":"2011","journal-title":"Acta Paediatr"},{"issue":"1","key":"2021120903442536400_B131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200725010-00006","article-title":"Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.","volume":"25","author":"Nuijten","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"2021120903442536400_B132","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s10096-012-1617-7","article-title":"A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).","volume":"31","author":"Paes","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"2021120903442536400_B133","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3111\/13696998.2010.499749","article-title":"The cost effectiveness of palivizumab: a systematic review of the evidence.","volume":"13","author":"Smart","year":"2010","journal-title":"J Med Econ"},{"issue":"5","key":"2021120903442536400_B134","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3111\/13696998.2012.672942","article-title":"Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.","volume":"15","author":"Weiner","year":"2012","journal-title":"J Med Econ"},{"issue":"10","key":"2021120903442536400_B135","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/archpedi.160.10.1070","article-title":"Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.","volume":"160","author":"Elhassan","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"5","key":"2021120903442536400_B136","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14737167.7.5.445","article-title":"Cost-effectiveness of palivizumab in infancy.","volume":"7","author":"Embleton","year":"2007","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7447","key":"2021120903442536400_B137","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/bmj.328.7447.1026","article-title":"Prevention of respiratory syncytial virus infection in infants.","volume":"328","author":"Handforth","year":"2004","journal-title":"BMJ"},{"issue":"3 pt 1","key":"2021120903442536400_B138","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1542\/peds.104.3.419","article-title":"Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.","volume":"104","author":"Joffe","year":"1999","journal-title":"Pediatrics"},{"issue":"4","key":"2021120903442536400_B139","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00431-002-1105-7","article-title":"Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.","volume":"162","author":"Liese","year":"2003","journal-title":"Eur J Pediatr"},{"issue":"4","key":"2021120903442536400_B140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/11531860-000000000-00000","article-title":"Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.","volume":"28","author":"Prescott","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2021120903442536400_B141","first-page":"77","article-title":"Respiratory syncytial virus prophylaxis in special populations: Is it something worth considering in cystic fibrosis and immunosuppression?","volume":"16","author":"Prescott","year":"2011","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"7","key":"2021120903442536400_B142","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/adc.2008.155556","article-title":"Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.","volume":"95","author":"Rietveld","year":"2010","journal-title":"Arch Dis Child"},{"issue":"6","key":"2021120903442536400_B143","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1542\/peds.2004-0959","article-title":"Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.","volume":"114","author":"Wegner","year":"2004","journal-title":"Pediatrics"},{"issue":"3","key":"2021120903442536400_B144","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-154-3-201102010-00007","article-title":"High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions.","volume":"154","author":"Owens","year":"2011","journal-title":"Ann Intern Med"},{"issue":"5","key":"2021120903442536400_B145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/imt.10.53","article-title":"Therapeutic targeting of respiratory syncytial virus G-protein.","volume":"2","author":"Kauvar","year":"2010","journal-title":"Immunotherapy"},{"issue":"12","key":"2021120903442536400_B146","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2021120903442536400_B147","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jir622","article-title":"Nanobodies\u00ae specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.","volume":"204","author":"Schepens","year":"2011","journal-title":"J Infect Dis"},{"issue":"19","key":"2021120903442536400_B148","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2021120903442536400_B149","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/651603","article-title":"Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.","volume":"50","author":"Empey","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2021120903442536400_B150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"2021120903442536400_B151","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1093\/infdis\/jit512","article-title":"Progress and challenges in RSV prophylaxis and vaccine development.","volume":"208","author":"Haynes","year":"2013","journal-title":"J Infect Dis"},{"issue":"9725","key":"2021120903442536400_B152","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"40","key":"2021120903442536400_B153","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/j.vaccine.2013.07.024","article-title":"Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.","volume":"31","author":"R\u00e9gnier","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"2021120903442536400_B154","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JVI.02769-12","article-title":"Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.","volume":"87","author":"Luongo","year":"2013","journal-title":"J Virol"},{"issue":"8","key":"2021120903442536400_B155","doi-asserted-by":"crossref","first-page":"e71072","DOI":"10.1371\/journal.pone.0071072","article-title":"A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.","volume":"8","author":"Rigter","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"2021120903442536400_B156","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021120903442536400_B157","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.vaccine.2012.11.009","article-title":"Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.","volume":"31","author":"Glenn","year":"2013","journal-title":"Vaccine"},{"issue":"6158","key":"2021120903442536400_B158","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/2\/e620\/1103824\/peds_2014-1666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/2\/e620\/1103824\/peds_2014-1666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T19:26:18Z","timestamp":1639077978000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/134\/2\/e620\/32961\/Updated-Guidance-for-Palivizumab-Prophylaxis-Among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":158,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,8,1]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-1666","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,1]]}}}